RJA
MDGL icon

Raymond James & Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

Raymond James & Associates’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.12M Sell
19,433
-888
-4% -$227K ﹤0.01% 1781
2024
Q2 		$5.69M Buy
20,321
+37
+0.2% +$8.81K ﹤0.01% 1493
2024
Q1 		$5.42M Buy
20,284
+554
+3% +$131K ﹤0.01% 1524
2023
Q4 		$4.57M Sell
19,730
-721
-4% -$126K ﹤0.01% 1603
2023
Q3 		$2.99M Buy
20,451
+5,295
+35% +$997K ﹤0.01% 1780
2023
Q2 		$3.5M Buy
+15,156
New +$4.1M ﹤0.01% 1721
2014
Q1 		– Sell
-2,588
Closed -$475K – 2109
2013
Q4 		$475K Buy
+2,588
New +$474K ﹤0.01% 1689

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Raymond James & Associates's MDGL Position: Q3 2024 in Review

Raymond James & Associates reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.4% in Q3 2024, selling an estimated $227K and leaving 19,433 shares worth $4.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1781.

Raymond James & Associates first reported a position in MDGL in Q4 2013 and has held it in 7 quarters since. The position peaked at $5.69M in Q2 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • Raymond James & Associates held 19,433 shares of Madrigal Pharmaceuticals worth $4.12M as of Q3 2024.
  • Raymond James & Associates sold 888 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $227K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1781 holding.
  • Raymond James & Associates first reported a position in Madrigal Pharmaceuticals in Q4 2013 and has held it in 7 quarters since.
  • Raymond James & Associates's Madrigal Pharmaceuticals position peaked at $5.69M in Q2 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.